# Amelia Degenkolb

> Amelia Degenkolb is the CEO and co-founder of Novocuff, a Mountain View medical device company building the Cervical Control System, a device designed to stabilize the cervix, retain amniotic fluid and prolong pregnancies threatened by preterm premature rupture of membranes. A biomedical engineer who spent seven years as the first employee and lead engineer at Alydia Health, she helped bring the Jada System for postpartum hemorrhage to market before that company's $240M acquisition by Organon. In July 2024 she raised an oversubscribed $26M Series A to fund a U.S. pivotal trial aimed at reducing preterm births, the leading cause of infant mortality worldwide.

- **Role:** CEO and Co-founder at Novocuff, Inc.
- **Organizations:** Novocuff, Inc., Alydia Health (formerly InPress Technologies), Fogarty Innovation
- **From:** Berkeley, California, United States
- **Nationality:** American
- **Education:** Began undergraduate studies, University of Massachusetts, Amherst, B.A., interdisciplinary studies with an ethics in engineering emphasis (Division 1 water polo), University of California, Berkeley, M.S. in Biomedical Engineering, California Polytechnic State University, San Luis Obispo
- **Known for:** Co-founded and leads Novocuff, raising an oversubscribed $26M Series A in July 2024 (total funding ~$28M), As first employee and lead engineer at Alydia Health, helped develop the Jada System and change the standard of care for postpartum hemorrhage, Alydia Health was acquired by Organon for $240M

## Career timeline

- **2012** — Earned M.S. in Biomedical Engineering from Cal Poly San Luis Obispo
- **2012-2019** — First employee and lead engineer at Alydia Health, developing the Jada System for postpartum hemorrhage over roughly seven years
- **2021** — Co-founded Novocuff with Donald Lee after Alydia Health's acquisition by Organon for $240M
- **2022** — Won $70,000 at AngelCon and gold prize plus $15,000 at the Impact1 Fetal & Maternal Pitch Competition at Stanford
- **2023** — Named a Ferolyn Fellow; spoke at the NIH Innovations in Maternal Health Workshop
- **2024** — Raised an oversubscribed $26M Series A led by AXA IM Alts to advance preterm birth prevention technology
- **2025** — Advanced toward a U.S. multi-center pivotal clinical trial (RETAIN study) for the Cervical Control System

## Achievements

- Co-founded and leads Novocuff, raising an oversubscribed $26M Series A in July 2024 (total funding ~$28M)
- As first employee and lead engineer at Alydia Health, helped develop the Jada System and change the standard of care for postpartum hemorrhage
- Alydia Health was acquired by Organon for $240M
- Won $70,000 in equity-backed funding at AngelCon 2022
- Won the gold prize and $15,000 at the Impact1 Fetal & Maternal Pitch Competition at Stanford
- Named a 2023 Ferolyn Fellow for healthcare innovation leadership
- Spoke at the NIH Innovations in Maternal Health Workshop

## Latest updates

- **2024-07** — Novocuff raised an oversubscribed $26M Series A led by AXA IM Alts, with Laerdal Million Lives Fund, Laborie, RH Capital, Avestria Ventures and March of Dimes participating.
- **2025-01** — Company advancing toward a U.S. multi-center pivotal clinical trial (RETAIN study) of the Cervical Control System for PPROM, pending FDA approval under an Investigational Device Exemption.

## Links

- Website: https://novocuff.com
- LinkedIn: http://www.linkedin.com/in/amelia-degenkolb-48b07124

---

Profile page: https://yespress.io/amelia-degenkolb
Published by YesPress — https://yespress.io
Last updated: 2026-06-14